argenx SE/$ARGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Ticker
$ARGX
Sector
Primary listing
Employees
1,863
Headquarters
Website
argenx SE Metrics
BasicAdvanced
$57bn
35.03
$26.21
-0.02
-
Price and volume
Market cap
$57bn
Beta
-0.02
52-week high
$953.58
52-week low
$587.37
Average daily volume
354k
Financial strength
Current ratio
5.123
Quick ratio
4.524
Long term debt to equity
0.428
Total debt to equity
0.558
Interest coverage (TTM)
504.45%
Profitability
EBITDA (TTM)
1,612.902
Gross margin (TTM)
59.07%
Net profit margin (TTM)
32.26%
Operating margin (TTM)
30.13%
Effective tax rate (TTM)
1.81%
Revenue per employee (TTM)
$2,850,000
Management effectiveness
Return on assets (TTM)
11.63%
Return on equity (TTM)
23.63%
Valuation
Price to earnings (TTM)
35.028
Price to revenue (TTM)
10.688
Price to book
5.98
Price to tangible book (TTM)
6.17
Price to free cash flow (TTM)
62.878
Free cash flow yield (TTM)
1.59%
Free cash flow per share (TTM)
14.603
Growth
Revenue change (TTM)
70.30%
Earnings per share change (TTM)
39.82%
3-year revenue growth (CAGR)
85.31%
10-year revenue growth (CAGR)
80.64%
3-year earnings per share growth (CAGR)
54.19%
10-year earnings per share growth (CAGR)
37.57%
argenx SE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.